Patient Derived Xenograft (PDX) Models Market Market Research Report 2033
Patient Derived Xenograft (PDX) Models Market Market Research Report 2033
Segments - by Type (Mice Models, Rat Models, Others), by Tumor Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Hematological Cancer, Pancreatic Cancer, Others), by Application (Preclinical Drug Development, Biomarker Analysis, Personalized Medicine, Oncology Research, Others), by End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, Others)
Upcoming
| Report ID :HC-2512
| 4.3 Rating
| 66 Reviews
| 276 Pages
| Format :
Report Description
Patient Derived Xenograft (PDX) Models Market Outlook
According to our latest research, the global Patient Derived Xenograft (PDX) Models market size reached USD 283.5 million in 2024 and is projected to grow at a robust CAGR of 15.2% through the forecast period, reaching a value of USD 959.3 million by 2033. This significant growth is driven by the increasing adoption of PDX models in oncology research, drug development, and personalized medicine, as pharmaceutical companies and research organizations seek more predictive and translatable preclinical models. The market is witnessing considerable momentum as the demand for more accurate and reliable cancer models accelerates, especially in the context of rising cancer incidences and the growing emphasis on targeted therapeutics.
One of the primary growth factors for the Patient Derived Xenograft (PDX) Models market is the increasing prevalence of cancer worldwide. According to the World Health Organization, cancer remains a leading cause of morbidity and mortality globally, with over 19 million new cases reported in 2024. This alarming rise in cancer incidence has intensified the need for advanced research models that can closely mimic human tumor biology. PDX models, which involve implanting human tumor tissues into immunodeficient mice or rats, offer a higher degree of translational relevance compared to traditional cell line xenograft models. As a result, pharmaceutical and biotechnology companies are increasingly investing in PDX-based studies to improve the predictability of clinical outcomes and reduce the attrition rates of oncology drug candidates.
Another key driver propelling the growth of the Patient Derived Xenograft (PDX) Models market is the shift towards personalized medicine and biomarker-driven therapies. PDX models enable researchers to evaluate the efficacy of novel drugs on patient-specific tumor samples, thereby facilitating the development of tailored therapeutic regimens. This approach not only enhances the probability of clinical success but also supports the identification of predictive biomarkers for patient stratification. The growing adoption of PDX models in biomarker analysis and personalized medicine is further supported by advancements in genomics, high-throughput screening, and molecular profiling technologies, which are enabling more detailed characterization of tumor heterogeneity and response mechanisms.
The Patient Derived Xenograft (PDX) Models market is also benefiting from increased collaborations between academic research institutes, contract research organizations (CROs), and pharmaceutical companies. These collaborations are fostering innovation in preclinical drug development and expanding the availability of well-characterized PDX repositories. In addition, regulatory agencies are recognizing the value of PDX models in bridging the gap between preclinical and clinical research, which is encouraging their integration into drug discovery pipelines. However, the high cost of PDX model development and ethical concerns related to animal use continue to pose challenges. Despite these hurdles, the market is expected to maintain its upward trajectory, driven by sustained investments in oncology research and the growing need for more predictive preclinical models.
From a regional perspective, North America currently dominates the global Patient Derived Xenograft (PDX) Models market, accounting for the largest share due to its advanced healthcare infrastructure, strong presence of pharmaceutical and biotechnology companies, and significant funding for cancer research. Europe follows closely, supported by robust research initiatives and increasing adoption of personalized medicine approaches. The Asia Pacific region is emerging as a lucrative market, fueled by rising cancer prevalence, improving research capabilities, and growing investments from both public and private sectors. Latin America and the Middle East & Africa are also witnessing gradual growth, although their market shares remain comparatively smaller due to limited research infrastructure and funding constraints.
Type Analysis
The Patient Derived Xenograft (PDX) Models market, when segmented by type, primarily includes Mice Models, Rat Models, and other emerging animal models. Among these, mice models hold the dominant share, accounting for over 75% of the market in 2024. This dominance is attributed to the extensive use of immunodeficient mouse strains, such as NOD/SCID and NSG mice, which are highly receptive to human tumor engraftment and provide a reliable platform for tumor growth and drug testing. Mice models are widely preferred due to their relatively lower cost, ease of genetic manipulation, and the availability of well-established protocols for tumor implantation and monitoring. These advantages make mice models the first choice for preclinical oncology research and pharmaceutical drug testing.
Rat models, while representing a smaller portion of the Patient Derived Xenograft (PDX) Models market, are gaining traction due to their larger size, which allows for more extensive sampling, imaging, and surgical interventions. Rats offer certain physiological and anatomical similarities to humans that can be advantageous in specific research applications, such as pharmacokinetics and toxicology studies. The development of immunodeficient rat strains has further facilitated the adoption of rat PDX models, particularly in studies requiring larger tissue volumes or more complex surgical procedures. However, higher maintenance costs and longer gestation periods compared to mice have limited their widespread adoption.
Other animal models, including zebrafish and rabbits, are emerging as alternative platforms in the Patient Derived Xenograft (PDX) Models market. These models are being explored for their unique advantages in specific research contexts, such as rapid tumor growth in zebrafish or the ability to perform long-term studies in rabbits. While these models currently occupy a niche segment, ongoing research and technological advancements may expand their applications in the coming years. The integration of innovative imaging techniques and genetic engineering tools is expected to enhance the utility and translational relevance of these alternative models.
The choice of animal model in PDX research is heavily influenced by the specific research objectives, tumor type, and resource availability. While mice models continue to dominate due to their versatility and cost-effectiveness, the growing interest in rat and other animal models reflects the evolving needs of the research community. The Patient Derived Xenograft (PDX) Models market is expected to witness further diversification in model types as researchers seek to overcome the limitations of traditional models and address the complexities of human cancer biology more effectively.
Overall, the type segment analysis underscores the critical role of animal model selection in the success of PDX-based research. As the demand for more predictive and clinically relevant preclinical models increases, the Patient Derived Xenograft (PDX) Models market is likely to see continued innovation in model development and validation, supporting the advancement of oncology drug discovery and personalized medicine.
Report Scope
| Attributes | Details |
| Report Title | Patient Derived Xenograft (PDX) Models Market Market Research Report 2033 |
| By Type | Mice Models, Rat Models, Others |
| By Tumor Type | Lung Cancer, Breast Cancer, Colorectal Cancer, Hematological Cancer, Pancreatic Cancer, Others |
| By Application | Preclinical Drug Development, Biomarker Analysis, Personalized Medicine, Oncology Research, Others |
| By End-User | Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, Others |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2024 |
| Historic Data | 2018-2023 |
| Forecast Period | 2025-2033 |
| Number of Pages | 276 |
| Number of Tables & Figures | 318 |
| Customization Available | Yes, the report can be customized as per your need. |
Tumor Type Analysis
The Patient Derived Xenograft (PDX) Models market, segmented by tumor type, addresses a broad spectrum of cancers, including Lung Cancer, Breast Cancer, Colorectal Cancer, Hematological Cancer, Pancreatic Cancer, and others. Among these, breast cancer PDX models constitute the largest market share, driven by the high global incidence of breast cancer and the urgent need for more effective therapies. These models are extensively used to study tumor heterogeneity, drug resistance mechanisms, and the efficacy of novel targeted agents. The availability of well-characterized breast cancer PDX repositories has further accelerated research in this area, enabling the identification of predictive biomarkers and the development of personalized treatment strategies.
Lung cancer PDX models represent another significant segment, reflecting the high mortality rate associated with lung cancer and the challenges in developing effective therapies. These models provide a valuable platform for evaluating the efficacy of new drugs, studying tumor microenvironment interactions, and exploring mechanisms of resistance to existing treatments. The complexity and heterogeneity of lung tumors necessitate the use of PDX models to capture the diversity of patient responses and guide the development of more effective therapeutic approaches.
Colorectal cancer PDX models are also gaining prominence in the Patient Derived Xenograft (PDX) Models market, as colorectal cancer remains one of the most common malignancies worldwide. These models are crucial for understanding the molecular underpinnings of colorectal tumorigenesis, assessing the efficacy of chemotherapeutic agents, and developing combination therapies. The integration of genomic and transcriptomic analyses with PDX studies is enabling researchers to uncover novel therapeutic targets and optimize treatment regimens for colorectal cancer patients.
Hematological cancer PDX models, including those for leukemia, lymphoma, and multiple myeloma, are increasingly being utilized to investigate disease mechanisms and evaluate new therapeutic agents. These models are particularly valuable for studying the clonal evolution of hematological malignancies, testing immunotherapies, and identifying resistance pathways. Pancreatic cancer PDX models, although representing a smaller segment, are critical for addressing the urgent need for effective treatments in this highly lethal cancer type. The poor prognosis and limited therapeutic options for pancreatic cancer have driven significant investment in PDX-based research to accelerate drug discovery and development.
The 'others' category in the tumor type segment encompasses a range of solid and rare tumors, reflecting the expanding scope of PDX model applications in oncology research. The growing demand for PDX models across diverse tumor types underscores their importance in advancing cancer research and supporting the development of more effective, patient-specific therapies. As the Patient Derived Xenograft (PDX) Models market continues to evolve, the tumor type segment will remain a key driver of innovation and growth.
Application Analysis
The application segment of the Patient Derived Xenograft (PDX) Models market is broad and multifaceted, encompassing Preclinical Drug Development, Biomarker Analysis, Personalized Medicine, Oncology Research, and other specialized uses. Preclinical drug development remains the largest application, accounting for more than 40% of the market in 2024. PDX models are considered the gold standard for evaluating the efficacy and safety of novel anticancer agents before they enter clinical trials. By closely mimicking human tumor biology, these models provide more reliable predictions of clinical outcomes, thereby reducing the risk of late-stage failures and optimizing the drug development process.
Biomarker analysis is another rapidly growing application within the Patient Derived Xenograft (PDX) Models market. The ability to correlate drug responses with specific molecular and genetic features of patient-derived tumors is transforming the landscape of oncology research. PDX models enable the identification and validation of predictive biomarkers, which are essential for patient stratification and the development of targeted therapies. The integration of next-generation sequencing, proteomics, and other advanced technologies is further enhancing the utility of PDX models in biomarker discovery and validation.
Personalized medicine represents a transformative application of PDX models, as it allows for the customization of treatment regimens based on individual patient tumor characteristics. By testing multiple therapeutic options on patient-specific PDX models, clinicians can identify the most effective treatment strategy for each patient. This approach not only improves clinical outcomes but also minimizes unnecessary side effects and reduces healthcare costs. The growing emphasis on personalized medicine is expected to drive sustained demand for PDX models, particularly as healthcare systems increasingly adopt precision oncology approaches.
Oncology research, encompassing both basic and translational studies, is a fundamental application area for PDX models. Researchers use these models to study tumor biology, elucidate mechanisms of drug resistance, and explore the interactions between tumors and their microenvironment. The insights gained from PDX-based research are critical for the development of new therapeutic targets and the optimization of existing treatments. Other applications, such as immuno-oncology studies and the evaluation of combination therapies, are also gaining traction as the Patient Derived Xenograft (PDX) Models market continues to expand.
Overall, the application segment analysis highlights the versatility and transformative potential of PDX models across the drug development continuum. As the demand for more predictive and clinically relevant preclinical models grows, the Patient Derived Xenograft (PDX) Models market is poised for continued expansion, driven by advances in technology, increasing research investments, and the evolving needs of the oncology community.
End-User Analysis
The end-user segment of the Patient Derived Xenograft (PDX) Models market includes Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutes, and other specialized entities. Pharmaceutical and biotechnology companies represent the largest end-user group, accounting for over 50% of the market in 2024. These organizations rely heavily on PDX models to enhance the predictability of preclinical studies, accelerate drug discovery, and optimize clinical trial design. The integration of PDX models into pharmaceutical R&D pipelines is driven by the need to reduce attrition rates, improve translational relevance, and meet regulatory expectations for robust preclinical data.
Contract Research Organizations (CROs) are emerging as key players in the Patient Derived Xenograft (PDX) Models market, offering specialized services to pharmaceutical companies and academic institutions. CROs provide end-to-end solutions, including model development, drug efficacy testing, biomarker analysis, and data interpretation. The outsourcing of PDX-based research to CROs is gaining popularity due to cost efficiencies, access to specialized expertise, and the ability to scale studies rapidly. As the demand for PDX models grows, CROs are expanding their service portfolios and investing in the development of large, well-characterized PDX repositories.
Academic and research institutes play a pivotal role in advancing the science of PDX models and driving innovation in oncology research. These institutions are at the forefront of developing new PDX models, exploring novel applications, and conducting translational studies that bridge the gap between laboratory research and clinical practice. Collaborative partnerships between academia, industry, and government agencies are fostering the exchange of knowledge, resources, and technologies, thereby accelerating the adoption of PDX models in cancer research.
The 'others' category in the end-user segment includes government agencies, non-profit organizations, and independent research laboratories that utilize PDX models for various research and public health initiatives. These entities contribute to the expansion of PDX model applications beyond traditional drug development, including epidemiological studies, health policy research, and the evaluation of public health interventions. The growing diversity of end-users reflects the broad applicability and value of PDX models across the biomedical research ecosystem.
In summary, the end-user analysis underscores the central role of pharmaceutical and biotechnology companies in driving market growth, while highlighting the increasing contributions of CROs, academic institutions, and other stakeholders. The collaborative and multidisciplinary nature of PDX-based research is expected to sustain the momentum of the Patient Derived Xenograft (PDX) Models market in the years ahead.
Opportunities & Threats
The Patient Derived Xenograft (PDX) Models market presents significant opportunities for growth, particularly in the context of precision oncology and personalized medicine. The increasing availability of advanced genomic and molecular profiling technologies is enabling researchers to develop more sophisticated and clinically relevant PDX models. These advancements are opening new avenues for biomarker discovery, patient stratification, and the development of targeted therapies. As healthcare systems worldwide shift towards personalized medicine, the demand for PDX models is expected to rise, creating opportunities for market players to expand their product offerings, develop new services, and enter untapped markets.
Another major opportunity lies in the expansion of PDX model applications beyond oncology. While cancer research remains the primary focus, there is growing interest in utilizing PDX models for the study of other diseases, such as infectious diseases, autoimmune disorders, and rare genetic conditions. The versatility of PDX models, coupled with advancements in animal model development and genetic engineering, is enabling researchers to explore new therapeutic areas and address unmet medical needs. Additionally, the increasing trend of public-private partnerships and collaborative research initiatives is fostering innovation and accelerating the adoption of PDX models across diverse research domains.
Despite the promising outlook, the Patient Derived Xenograft (PDX) Models market faces several restraining factors that could impede its growth. One of the primary challenges is the high cost and complexity of developing and maintaining PDX models, which can limit their accessibility, particularly for smaller research organizations and institutions in developing regions. Ethical concerns related to the use of animals in research and the need for stringent regulatory compliance also pose significant barriers. Furthermore, the variability in engraftment rates and the potential for genetic drift during serial passaging of tumors can impact the reproducibility and reliability of PDX-based studies. Addressing these challenges will require continued investment in technology development, regulatory harmonization, and the establishment of best practices for PDX model generation and use.
Regional Outlook
North America remains the largest regional market for Patient Derived Xenograft (PDX) Models, accounting for approximately 48% of the global market in 2024, which translates to a value of around USD 136.1 million. The region's dominance is underpinned by a well-established healthcare infrastructure, strong presence of leading pharmaceutical and biotechnology companies, and substantial funding for cancer research. The United States, in particular, is a major hub for PDX model development, with numerous academic institutions, CROs, and industry players actively engaged in advancing PDX-based research. The region is also characterized by a high degree of regulatory support and a strong focus on innovation, which is driving the adoption of PDX models across a wide range of applications.
Europe holds the second-largest share of the Patient Derived Xenograft (PDX) Models market, with a market size of approximately USD 79.4 million in 2024. The region is witnessing steady growth, supported by robust research initiatives, increasing investments in personalized medicine, and the presence of leading academic and research institutions. Countries such as Germany, the United Kingdom, and France are at the forefront of PDX model research, leveraging advanced technologies and collaborative networks to drive innovation. The European market is expected to grow at a CAGR of 14.8% during the forecast period, reflecting the region's commitment to advancing precision oncology and translational research.
The Asia Pacific region is emerging as a high-growth market for Patient Derived Xenograft (PDX) Models, with a market size of USD 45.4 million in 2024 and a projected CAGR of 17.1% through 2033. The rapid growth in this region is driven by rising cancer incidence, improving healthcare infrastructure, and increasing investments in biomedical research. China, Japan, and India are leading the adoption of PDX models, supported by government initiatives, expanding research capabilities, and a growing focus on precision medicine. While Latin America and the Middle East & Africa currently represent smaller market shares, they are expected to witness gradual growth as research infrastructure and funding improve in these regions.
Competitor Outlook
The competitive landscape of the Patient Derived Xenograft (PDX) Models market is characterized by the presence of both established players and emerging companies, each striving to expand their market share through innovation, strategic partnerships, and the development of comprehensive PDX model repositories. Leading companies are investing heavily in research and development to enhance the translational relevance of their models, improve engraftment rates, and expand their portfolios to cover a wider range of tumor types and applications. The market is also witnessing an increasing trend of mergers and acquisitions, as companies seek to strengthen their capabilities and broaden their geographic reach.
Collaboration is a key theme in the Patient Derived Xenograft (PDX) Models market, with companies forming partnerships with academic institutions, CROs, and pharmaceutical firms to accelerate model development and validation. These collaborations are facilitating the sharing of expertise, resources, and data, thereby enabling the rapid expansion of PDX repositories and the development of novel applications. The competitive environment is further intensified by the entry of new players, particularly in emerging markets, who are leveraging technological advancements and local expertise to carve out niche positions in the market.
Innovation remains a critical differentiator in the Patient Derived Xenograft (PDX) Models market, with companies focusing on the integration of advanced technologies such as next-generation sequencing, high-throughput screening, and artificial intelligence to enhance model characterization and data analysis. The ability to offer comprehensive, end-to-end solutions—from model development to data interpretation—is becoming increasingly important, as customers seek to streamline their research processes and reduce time-to-market for new therapeutics. Companies that can demonstrate robust quality control, regulatory compliance, and a track record of successful collaborations are well-positioned to succeed in this competitive market.
Some of the major companies operating in the Patient Derived Xenograft (PDX) Models market include Crown Bioscience Inc., The Jackson Laboratory, Charles River Laboratories International, Inc., Horizon Discovery Group plc, WuXi AppTec, Champions Oncology, Inc., Oncodesign, and Eurofins Scientific. Crown Bioscience is renowned for its extensive PDX model library and global reach, offering a wide range of oncology research services. The Jackson Laboratory is a leading provider of genetically defined mouse models and PDX services, with a strong focus on translational cancer research. Charles River Laboratories has a comprehensive portfolio of preclinical research services, including PDX model development and drug efficacy testing.
Horizon Discovery Group is recognized for its expertise in gene editing and the development of custom PDX models for oncology research. WuXi AppTec offers integrated research and development services, including PDX model generation, drug screening, and biomarker analysis. Champions Oncology specializes in personalized oncology solutions, leveraging its proprietary TumorGraft platform to support drug development and clinical decision-making. Oncodesign and Eurofins Scientific are also key players, offering a range of PDX-based services and solutions to support cancer research and drug discovery. These companies are continuously investing in technology, expanding their model libraries, and forming strategic partnerships to maintain their competitive edge in the rapidly evolving Patient Derived Xenograft (PDX) Models market.
Key Players
- Crown Bioscience
- The Jackson Laboratory
- Charles River Laboratories
- Horizon Discovery (PerkinElmer)
- WuXi AppTec
- Champions Oncology
- Envigo
- Oncodesign
- XenTech
- Pharmatest Services
- EPO Berlin-Buch GmbH
- Shanghai LIDE Biotech Co., Ltd.
- Hera BioLabs
- Abnova Corporation
- Explora BioLabs
- Urosphere
- InnoSer
- GemPharmatech
- J-Pharma Co., Ltd.
- BioReperia AB
Segments
The Patient Derived Xenograft (PDX) Models Market market has been segmented on the basis of
Type
- Mice Models
- Rat Models
- Others
Tumor Type
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Hematological Cancer
- Pancreatic Cancer
- Others
Application
- Preclinical Drug Development
- Biomarker Analysis
- Personalized Medicine
- Oncology Research
- Others
End-User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Academic & Research Institutes
- Others
Competitive Landscape
- Top players in the market include THE JACKSON LABORATORY, WuXi AppTec, Envigo, Oncodesign, and Charles River Laboratories. These companies are considered as key manufacturers of Patient Derived Xenograft (PDX) Models based on their revenue, research development (R&D) activities, product offerings, regional presence, and supply chain management system.
- The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunity for the Patient Derived Xenograft (PDX) Models market.
- On March 02, 2021, Explora BioLabs launched two facilities in San Diego, in the US. The launch of these facilities is expected to expand Explora BioLabs’s footprints in San Diego from seven to nine on-demand vivaria.
- On February 25, 2021, Charles River Laboratories, entered into a strategic partnership with Kibur Medical to offer exclusive access to its implantable microdevice (IMD) for in vivo preclinical oncology studies. Through this partnership, together with leading expertise in early-stage preclinical testing, researchers can utilize the Kibur technology to perform in vivo testing of multiple doses and multiple combinations of oncology or immune-oncology therapies in small cohorts of patient-derived xenograft (PDX), cell-line derived or syngeneic models.
- In January 2021, Endo International plc launched Authorized Generic Version of Amitiza (lubiprostone) Capsules in the US.
Frequently Asked Questions
Major manufactures include, THE JACKSON LABORATORY, WuXi AppTec, Envigo, Oncodesign, Charles River Laboratories, Explora BioLabs, Champions Oncology, Inc. and others.
Factors such as Surgical Treatment, Healthcare Expenditure, Technological Advancements, Export & Import Scenario, Price of Drugs, and GDP are analyzed in the final report.
The base year considered for the Global Patient Derived Xenograft (PDX) Models market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017, and 2018 are the historic years, and the forecast is provided from 2020 to 2027.
The market is expected to show decline of -3.2% in growth market between 2019 and 2020 owing to the COVID 19 pandemic effect on the Patient Derived Xenograft (PDX) Models market.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
Usage of PDX model in preclinical drug development, biomarker analysis, and basic cancer research studies are the major applications of the Patient Derived Xenograft (PDX) Models.
Rising governments support for pharmaceutical and biotechnology industries, growing demand for personalized medicines, increasing R&D activities by pharmaceutical and biotechnology companies, and surging number of preclinical studies for developing anti-cancer drugs for solid tumors are the factors expected to drive the market growth during forecast period.
In addition to market size (in US$ Million), Company Market Share (in % for base year 2019), Regulatory Landscape, Technology Landscape, Patent Analysis, Consumer Survey, and Pipeline/Clinical Trial Analysis.
According to this Growth Market Reports, the Patient Derived Xenograft (PDX) Models market is likely to register a CAGR of 14.5% during forecast period 2020-2027, with an anticipated valuation of USD 283.3 million by the end of the 2027.
Additional company profiles can be provided on request
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Patient Derived Xenograft (PDX) Models Market Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Patient Derived Xenograft (PDX) Models Market Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Patient Derived Xenograft (PDX) Models Market Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Patient Derived Xenograft (PDX) Models Market Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Patient Derived Xenograft (PDX) Models Market Market Size & Forecast, 2023-2032
4.5.1 Patient Derived Xenograft (PDX) Models Market Market Size and Y-o-Y Growth
4.5.2 Patient Derived Xenograft (PDX) Models Market Market Absolute $ Opportunity
Chapter 5 Global Patient Derived Xenograft (PDX) Models Market Market Analysis and Forecast By Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Type
5.1.2 Basis Point Share (BPS) Analysis By Type
5.1.3 Absolute $ Opportunity Assessment By Type
5.2 Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Type
5.2.1 Mice Models
5.2.2 Rat Models
5.2.3 Others
5.3 Market Attractiveness Analysis By Type
Chapter 6 Global Patient Derived Xenograft (PDX) Models Market Market Analysis and Forecast By Tumor Type
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Tumor Type
6.1.2 Basis Point Share (BPS) Analysis By Tumor Type
6.1.3 Absolute $ Opportunity Assessment By Tumor Type
6.2 Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Tumor Type
6.2.1 Lung Cancer
6.2.2 Breast Cancer
6.2.3 Colorectal Cancer
6.2.4 Hematological Cancer
6.2.5 Pancreatic Cancer
6.2.6 Others
6.3 Market Attractiveness Analysis By Tumor Type
Chapter 7 Global Patient Derived Xenograft (PDX) Models Market Market Analysis and Forecast By Application
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By Application
7.1.2 Basis Point Share (BPS) Analysis By Application
7.1.3 Absolute $ Opportunity Assessment By Application
7.2 Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Application
7.2.1 Preclinical Drug Development
7.2.2 Biomarker Analysis
7.2.3 Personalized Medicine
7.2.4 Oncology Research
7.2.5 Others
7.3 Market Attractiveness Analysis By Application
Chapter 8 Global Patient Derived Xenograft (PDX) Models Market Market Analysis and Forecast By End-User
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities By End-User
8.1.2 Basis Point Share (BPS) Analysis By End-User
8.1.3 Absolute $ Opportunity Assessment By End-User
8.2 Patient Derived Xenograft (PDX) Models Market Market Size Forecast By End-User
8.2.1 Pharmaceutical & Biotechnology Companies
8.2.2 Contract Research Organizations
8.2.3 Academic & Research Institutes
8.2.4 Others
8.3 Market Attractiveness Analysis By End-User
Chapter 9 Global Patient Derived Xenograft (PDX) Models Market Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities By Region
9.1.2 Basis Point Share (BPS) Analysis By Region
9.1.3 Absolute $ Opportunity Assessment By Region
9.2 Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis By Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America Patient Derived Xenograft (PDX) Models Market Analysis and Forecast
11.1 Introduction
11.2 North America Patient Derived Xenograft (PDX) Models Market Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Type
11.6.1 Mice Models
11.6.2 Rat Models
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis By Type
11.8 Absolute $ Opportunity Assessment By Type
11.9 Market Attractiveness Analysis By Type
11.10 North America Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Tumor Type
11.10.1 Lung Cancer
11.10.2 Breast Cancer
11.10.3 Colorectal Cancer
11.10.4 Hematological Cancer
11.10.5 Pancreatic Cancer
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis By Tumor Type
11.12 Absolute $ Opportunity Assessment By Tumor Type
11.13 Market Attractiveness Analysis By Tumor Type
11.14 North America Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Application
11.14.1 Preclinical Drug Development
11.14.2 Biomarker Analysis
11.14.3 Personalized Medicine
11.14.4 Oncology Research
11.14.5 Others
11.15 Basis Point Share (BPS) Analysis By Application
11.16 Absolute $ Opportunity Assessment By Application
11.17 Market Attractiveness Analysis By Application
11.18 North America Patient Derived Xenograft (PDX) Models Market Market Size Forecast By End-User
11.18.1 Pharmaceutical & Biotechnology Companies
11.18.2 Contract Research Organizations
11.18.3 Academic & Research Institutes
11.18.4 Others
11.19 Basis Point Share (BPS) Analysis By End-User
11.20 Absolute $ Opportunity Assessment By End-User
11.21 Market Attractiveness Analysis By End-User
Chapter 12 Europe Patient Derived Xenograft (PDX) Models Market Analysis and Forecast
12.1 Introduction
12.2 Europe Patient Derived Xenograft (PDX) Models Market Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Type
12.6.1 Mice Models
12.6.2 Rat Models
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis By Type
12.8 Absolute $ Opportunity Assessment By Type
12.9 Market Attractiveness Analysis By Type
12.10 Europe Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Tumor Type
12.10.1 Lung Cancer
12.10.2 Breast Cancer
12.10.3 Colorectal Cancer
12.10.4 Hematological Cancer
12.10.5 Pancreatic Cancer
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis By Tumor Type
12.12 Absolute $ Opportunity Assessment By Tumor Type
12.13 Market Attractiveness Analysis By Tumor Type
12.14 Europe Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Application
12.14.1 Preclinical Drug Development
12.14.2 Biomarker Analysis
12.14.3 Personalized Medicine
12.14.4 Oncology Research
12.14.5 Others
12.15 Basis Point Share (BPS) Analysis By Application
12.16 Absolute $ Opportunity Assessment By Application
12.17 Market Attractiveness Analysis By Application
12.18 Europe Patient Derived Xenograft (PDX) Models Market Market Size Forecast By End-User
12.18.1 Pharmaceutical & Biotechnology Companies
12.18.2 Contract Research Organizations
12.18.3 Academic & Research Institutes
12.18.4 Others
12.19 Basis Point Share (BPS) Analysis By End-User
12.20 Absolute $ Opportunity Assessment By End-User
12.21 Market Attractiveness Analysis By End-User
Chapter 13 Asia Pacific Patient Derived Xenograft (PDX) Models Market Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific Patient Derived Xenograft (PDX) Models Market Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Type
13.6.1 Mice Models
13.6.2 Rat Models
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis By Type
13.8 Absolute $ Opportunity Assessment By Type
13.9 Market Attractiveness Analysis By Type
13.10 Asia Pacific Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Tumor Type
13.10.1 Lung Cancer
13.10.2 Breast Cancer
13.10.3 Colorectal Cancer
13.10.4 Hematological Cancer
13.10.5 Pancreatic Cancer
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis By Tumor Type
13.12 Absolute $ Opportunity Assessment By Tumor Type
13.13 Market Attractiveness Analysis By Tumor Type
13.14 Asia Pacific Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Application
13.14.1 Preclinical Drug Development
13.14.2 Biomarker Analysis
13.14.3 Personalized Medicine
13.14.4 Oncology Research
13.14.5 Others
13.15 Basis Point Share (BPS) Analysis By Application
13.16 Absolute $ Opportunity Assessment By Application
13.17 Market Attractiveness Analysis By Application
13.18 Asia Pacific Patient Derived Xenograft (PDX) Models Market Market Size Forecast By End-User
13.18.1 Pharmaceutical & Biotechnology Companies
13.18.2 Contract Research Organizations
13.18.3 Academic & Research Institutes
13.18.4 Others
13.19 Basis Point Share (BPS) Analysis By End-User
13.20 Absolute $ Opportunity Assessment By End-User
13.21 Market Attractiveness Analysis By End-User
Chapter 14 Latin America Patient Derived Xenograft (PDX) Models Market Analysis and Forecast
14.1 Introduction
14.2 Latin America Patient Derived Xenograft (PDX) Models Market Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Type
14.6.1 Mice Models
14.6.2 Rat Models
14.6.3 Others
14.7 Basis Point Share (BPS) Analysis By Type
14.8 Absolute $ Opportunity Assessment By Type
14.9 Market Attractiveness Analysis By Type
14.10 Latin America Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Tumor Type
14.10.1 Lung Cancer
14.10.2 Breast Cancer
14.10.3 Colorectal Cancer
14.10.4 Hematological Cancer
14.10.5 Pancreatic Cancer
14.10.6 Others
14.11 Basis Point Share (BPS) Analysis By Tumor Type
14.12 Absolute $ Opportunity Assessment By Tumor Type
14.13 Market Attractiveness Analysis By Tumor Type
14.14 Latin America Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Application
14.14.1 Preclinical Drug Development
14.14.2 Biomarker Analysis
14.14.3 Personalized Medicine
14.14.4 Oncology Research
14.14.5 Others
14.15 Basis Point Share (BPS) Analysis By Application
14.16 Absolute $ Opportunity Assessment By Application
14.17 Market Attractiveness Analysis By Application
14.18 Latin America Patient Derived Xenograft (PDX) Models Market Market Size Forecast By End-User
14.18.1 Pharmaceutical & Biotechnology Companies
14.18.2 Contract Research Organizations
14.18.3 Academic & Research Institutes
14.18.4 Others
14.19 Basis Point Share (BPS) Analysis By End-User
14.20 Absolute $ Opportunity Assessment By End-User
14.21 Market Attractiveness Analysis By End-User
Chapter 15 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Type
15.6.1 Mice Models
15.6.2 Rat Models
15.6.3 Others
15.7 Basis Point Share (BPS) Analysis By Type
15.8 Absolute $ Opportunity Assessment By Type
15.9 Market Attractiveness Analysis By Type
15.10 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Tumor Type
15.10.1 Lung Cancer
15.10.2 Breast Cancer
15.10.3 Colorectal Cancer
15.10.4 Hematological Cancer
15.10.5 Pancreatic Cancer
15.10.6 Others
15.11 Basis Point Share (BPS) Analysis By Tumor Type
15.12 Absolute $ Opportunity Assessment By Tumor Type
15.13 Market Attractiveness Analysis By Tumor Type
15.14 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Market Size Forecast By Application
15.14.1 Preclinical Drug Development
15.14.2 Biomarker Analysis
15.14.3 Personalized Medicine
15.14.4 Oncology Research
15.14.5 Others
15.15 Basis Point Share (BPS) Analysis By Application
15.16 Absolute $ Opportunity Assessment By Application
15.17 Market Attractiveness Analysis By Application
15.18 Middle East & Africa (MEA) Patient Derived Xenograft (PDX) Models Market Market Size Forecast By End-User
15.18.1 Pharmaceutical & Biotechnology Companies
15.18.2 Contract Research Organizations
15.18.3 Academic & Research Institutes
15.18.4 Others
15.19 Basis Point Share (BPS) Analysis By End-User
15.20 Absolute $ Opportunity Assessment By End-User
15.21 Market Attractiveness Analysis By End-User
Chapter 16 Competition Landscape
16.1 Patient Derived Xenograft (PDX) Models Market Market: Competitive Dashboard
16.2 Global Patient Derived Xenograft (PDX) Models Market Market: Market Share Analysis, 2023
16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
16.3.1 Crown Bioscience
The Jackson Laboratory
Charles River Laboratories
Horizon Discovery (PerkinElmer)
WuXi AppTec
Champions Oncology
Envigo
Oncodesign
XenTech
Pharmatest Services
EPO Berlin-Buch GmbH
Shanghai LIDE Biotech Co., Ltd.
Hera BioLabs
Abnova Corporation
Explora BioLabs
Urosphere
InnoSer
GemPharmatech
J-Pharma Co., Ltd.
BioReperia AB
Methodology
Related Reports
Some other reports from this category!
Our Clients
